Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy [Yahoo! Finance]
Merus (NASDAQ: MRUS) had its price target raised by analysts at Citigroup Inc. from $89.00 to $97.00. They now have a "buy" rating on the stock.
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC [Yahoo! Finance]